The estimated Net Worth of Jay S Stout is at least $4.5 millió dollars as of 24 July 2024. Jay Stout owns over 2,813 units of Immunovant Inc stock worth over $4,210,100 and over the last 8 years Jay sold IMVT stock worth over $294,820.
Jay has made over 3 trades of the Immunovant Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Jay sold 2,813 units of IMVT stock worth $78,089 on 24 July 2024.
The largest trade Jay's ever made was selling 7,239 units of Immunovant Inc stock on 24 April 2024 worth over $209,207. On average, Jay trades about 1,863 units every 285 days since 2017. As of 24 July 2024 Jay still owns at least 144,926 units of Immunovant Inc stock.
You can see the complete history of Jay Stout stock trades at the bottom of the page.
Jay's mailing address filed with the SEC is C/O IMMUNOVANT, INC., 320 W 37TH STREET, 6TH FLOOR, NEW YORK, NY, 10018.
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann és Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Immunovant Inc executives and other stock owners filed with the SEC include: